

Paroxysmal Nocturnal Haemoglobinuria (PNH)


WHAT IS PNH?

Paroxysmal nocturnal haemoglobinuria (PNH) is a **rare, chronic, progressive, and potentially life-threatening blood disorder**.


PNH is characterised by **red blood cell (RBC) destruction** within blood vessels (also known as **intravascular haemolysis**, or IVH) and **white blood cell and platelet activation**, which may lead to blood clots (thrombosis).

PNH is caused by an **acquired genetic mutation** (not inherited) that may happen any time after birth and results in the **production of abnormal blood cells** that are **missing important protective blood cell surface proteins**. These missing proteins enable the complement system to 'attack' and **destroy or activate these abnormal blood cells**.^{1,2}


Circulatory system




PNH Blood Cell Destruction Within the Blood Vessels



THE COMPLEMENT SYSTEM



The complement system is a part of the immune system and is **essential to the body's defence against infection**.³



When the system is **thrown out of balance**, or dysregulated, these proteins can **trigger a dangerous, uncontrolled cascade of reactions** that attack cells and tissues resulting in **harmful inflammation** and the **destruction of healthy cells**.³

Diagnosed prevalence in adults is



~14K⁴



~6K⁴



~6K⁴



~2K⁴




PNH can occur in **children and adults** at any age; the average age of diagnosis is **in the 30s**.⁵

PNH affects both **men and women** and people of **every racial and ethnic group**.⁵

Living with PNH can be debilitating, and signs and symptoms may include⁵



Blood clots (thrombosis)



Abdominal pain



Difficulty swallowing




Erectile dysfunction



Shortness of breath



Excessive fatigue



Anaemia



Dark-coloured urine (haemoglobinuria)

PNH can lead to **thrombosis**, which can occur in blood vessels throughout the body, and/or damage to other vital organs, such as **kidneys and lungs**. This can result in an overall **impaired quality of life** and **potentially premature death**.^{1,5}

HOW IS PNH DIAGNOSED AND MONITORED?



Diverse symptoms and varied clinical presentation can delay diagnosis, in some cases by 10 or more years.⁶

PNH can be **diagnosed from a simple blood test** (high-sensitivity flow cytometry), which can detect and count PNH blood cells.^{7,8}

Another type of blood test is used to **monitor ongoing PNH disease activity**. This test measures lactate dehydrogenase (LDH), an enzyme that is released from red blood cells during IVH.⁷



Monitoring LDH regularly is a very important part of managing PNH. If high levels of LDH are present, it means that many red blood cells have been destroyed within blood vessels. This has been shown to correlate with complications, such as thrombosis and early mortality.²

Content created by Alexion, AstraZeneca Rare Disease

References:

1. Jang JH, et al. Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From a Korean PNH Registry. *J Korean Med Sci.* 2024 Mar 4;39(8):e81.
2. Rother RP, et al. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin. *JAMA.* 2005 Apr 6;293(13):1653-62.
3. Cedzyński M, et al. Editorial: The Role of Complement in Health and Disease. *Front. Immunol.* 2019;10:1869.
4. AstraZeneca Data on File - Epidemiology estimates are composed of a triangulation of different data sources including Data Monitor, Decision Resources Group, Kantar Health, and internal input. (Updated as of May 2024).
5. Shah N, et al. Paroxysmal Nocturnal Hemoglobinuria. *StatPearls.* 2023.
6. Mitchell R, et al. Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Internet-Based Survey by the Aplastic Anemia and MDS International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey. *SM Clin Med Oncol.* 2017; 1(1):1001.
7. Dezern AE, Borowitz MJ. ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 1 - Clinical Utility. *Cytometry Part B.* 2018; 94B:16-22.
8. Sutherland DR, et al. ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 2 - Reagent Selection and Assay Optimization for High-Sensitivity Testing. *Cytometry Part B.* 2018; 94B: 23-48.